Fri, Feb 27, 2015, 9:06 AM EST - U.S. Markets open in 24 mins.


% | $
Quotes you view appear here for quick access.

Sanofi Message Board

  • kmaggon kmaggon Dec 15, 2010 3:02 AM Flag

    Diabetes future

    The future diabetes treatment may lie in the monoclonal antibodies currently in R&D and clinical trials and stem cells.
    Mabs may shake up diabetes market

    The progress of monoclonal antibodies through clinical trials and regulatory approval pathway may shake up the entire diabetes market and declining insulin sales. The 2 most advanced mabs ate Otelixizumab and Xoma 052 in Phase III trials in diabetes. This is despite Phase III failure of Teplizumab.

    The first multimedia interactive review of the promising anti CD3 monoclonal antibody Otelixizumab (Tolerx, GSK) in diabetes type 1 is published. Otelixizumab (Tolerx, GSK) Diabetes Review (for smartphones/mobile devices)

48.87-0.04(-0.08%)Feb 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.